Adenosinergic Signaling in Epilepsy

Overview

Journal Neuropharmacology

Specialties Neurology
Pharmacology

Date 2015 Sep 6

PMID 26341819

Citations 63

Authors

Detlev Boison

Affiliations

Soon will be listed here.

Abstract

Despite the introduction of at least 20 new antiepileptic drugs (AEDs) into clinical practice over the past decades, about one third of all epilepsies remain refractory to conventional forms of treatment. In addition, currently used AEDs have been developed to suppress neuronal hyperexcitability, but not necessarily to address pathogenic mechanisms involved in epilepsy development or progression (epileptogenesis). For those reasons endogenous seizure control mechanisms of the brain may provide alternative therapeutic opportunities. Adenosine is a well characterized endogenous anticonvulsant and seizure terminator of the brain. Several lines of evidence suggest that endogenous adenosine-mediated seizure control mechanisms fail in chronic epilepsy, whereas therapeutic adenosine augmentation effectively prevents epileptic seizures, even those that are refractory to conventional AEDs. New findings demonstrate that dysregulation of adenosinergic mechanisms are intricately involved in the development of epilepsy and its comorbidities, whereas adenosine-associated epigenetic mechanisms may play a role in epileptogenesis. The first goal of this review is to discuss how maladaptive changes of adenosinergic mechanisms contribute to the expression of seizures (ictogenesis) and the development of epilepsy (epileptogenesis) by focusing on pharmacological (adenosine receptor dependent) and biochemical (adenosine receptor independent) mechanisms as well as on enzymatic and transport based mechanisms that control the availability (homeostasis) of adenosine. The second goal of this review is to highlight innovative adenosine-based opportunities for therapeutic intervention aimed at reconstructing normal adenosine function and signaling for improved seizure control in chronic epilepsy. New findings suggest that transient adenosine augmentation can have lasting epigenetic effects with disease modifying and antiepileptogenic outcome. This article is part of the Special Issue entitled 'Purines in Neurodegeneration and Neuroregeneration'.

Citing Articles

The cellular distribution of P2X7, P2Y6, and P2Y12 during or after pilocarpine-induced status epilepticus and literature review.

Li Y, Tang F, Luo Y Brain Circ. 2025; 10(4):343-353.

PMID: 40012593 PMC: 11850937. DOI: 10.4103/bc.bc_27_24.

Electroconvulsive therapy generates a postictal wave of spreading depolarization in mice and humans.

Rosenthal Z, Majeski J, Somarowthu A, Quinn D, Lindquist B, Putt M bioRxiv. 2024; .

PMID: 39554135 PMC: 11565954. DOI: 10.1101/2024.10.31.621357.

Pharmacology of Adenosine A Receptor Agonist in a Humanized Esterase Mouse Seizure Model Following Soman Intoxication.

Shih T, Munoz C, Acon-Chen C, Keith Z Neurotox Res. 2024; 42(5):41.

PMID: 39230655 PMC: 11374867. DOI: 10.1007/s12640-024-00717-z.

The Purinergic P2X7 Receptor as a Target for Adjunctive Treatment for Drug-Refractory Epilepsy.

Thakku Sivakumar D, Jain K, Alfehaid N, Wang Y, Teng X, Fischer W Int J Mol Sci. 2024; 25(13).

PMID: 39000004 PMC: 11241490. DOI: 10.3390/ijms25136894.

Effect of adenosinergic manipulations on amygdala-kindled seizures in mice: Implications for sudden unexpected death in epilepsy.

Purnell B, Petrucci A, Li R, Buchanan G Epilepsia. 2024; 65(9):2812-2826.

PMID: 38980980 PMC: 11534534. DOI: 10.1111/epi.18059.

References

Haydon P, Carmignoto G . Astrocyte control of synaptic transmission and neurovascular coupling. Physiol Rev. 2006; 86(3):1009-31. DOI: 10.1152/physrev.00049.2005. View

Chiari A, Yaksh T, Myers R, Provencher J, Moore L, Lee C . Preclinical toxicity screening of intrathecal adenosine in rats and dogs. Anesthesiology. 1999; 91(3):824-32. DOI: 10.1097/00000542-199909000-00035. View

Tian G, Azmi H, Takano T, Xu Q, Peng W, Lin J . An astrocytic basis of epilepsy. Nat Med. 2005; 11(9):973-81. PMC: 1850946. DOI: 10.1038/nm1277. View

Orr A, Hsiao E, Wang M, Ho K, Kim D, Wang X . Astrocytic adenosine receptor A2A and Gs-coupled signaling regulate memory. Nat Neurosci. 2015; 18(3):423-34. PMC: 4340760. DOI: 10.1038/nn.3930. View

Li T, Ren G, Kaplan D, Boison D . Human mesenchymal stem cell grafts engineered to release adenosine reduce chronic seizures in a mouse model of CA3-selective epileptogenesis. Epilepsy Res. 2009; 84(2-3):238-41. PMC: 2746090. DOI: 10.1016/j.eplepsyres.2009.01.002. View

Nilsen K, Cock H . Focal treatment for refractory epilepsy: hope for the future?. Brain Res Brain Res Rev. 2004; 44(2-3):141-53. DOI: 10.1016/j.brainresrev.2003.11.003. View

Boison D . Adenosine augmentation therapies (AATs) for epilepsy: prospect of cell and gene therapies. Epilepsy Res. 2009; 85(2-3):131-41. PMC: 2713801. DOI: 10.1016/j.eplepsyres.2009.03.019. View

Lovatt D, Xu Q, Liu W, Takano T, Smith N, Schnermann J . Neuronal adenosine release, and not astrocytic ATP release, mediates feedback inhibition of excitatory activity. Proc Natl Acad Sci U S A. 2012; 109(16):6265-70. PMC: 3341061. DOI: 10.1073/pnas.1120997109. View

DAlimonte I, DAuro M, Citraro R, Biagioni F, Jiang S, Nargi E . Altered distribution and function of A2A adenosine receptors in the brain of WAG/Rij rats with genetic absence epilepsy, before and after appearance of the disease. Eur J Neurosci. 2009; 30(6):1023-35. DOI: 10.1111/j.1460-9568.2009.06897.x. View

10.

Pardo C, Nabbout R, Galanopoulou A . Mechanisms of epileptogenesis in pediatric epileptic syndromes: Rasmussen encephalitis, infantile spasms, and febrile infection-related epilepsy syndrome (FIRES). Neurotherapeutics. 2014; 11(2):297-310. PMC: 3996116. DOI: 10.1007/s13311-014-0265-2. View

11.

Fedele D, Li T, Lan J, Fredholm B, Boison D . Adenosine A1 receptors are crucial in keeping an epileptic focus localized. Exp Neurol. 2006; 200(1):184-90. DOI: 10.1016/j.expneurol.2006.02.133. View

12.

Malmgren K, Thom M . Hippocampal sclerosis--origins and imaging. Epilepsia. 2012; 53 Suppl 4:19-33. DOI: 10.1111/j.1528-1167.2012.03610.x. View

13.

Etherington L, Patterson G, Meechan L, Boison D, Irving A, Dale N . Astrocytic adenosine kinase regulates basal synaptic adenosine levels and seizure activity but not activity-dependent adenosine release in the hippocampus. Neuropharmacology. 2008; 56(2):429-37. PMC: 9972962. DOI: 10.1016/j.neuropharm.2008.09.016. View

14.

Fisher R, Vickrey B, Gibson P, Hermann B, Penovich P, Scherer A . The impact of epilepsy from the patient's perspective I. Descriptions and subjective perceptions. Epilepsy Res. 2000; 41(1):39-51. DOI: 10.1016/s0920-1211(00)00126-1. View

15.

Bell B, Lin J, Seidenberg M, Hermann B . The neurobiology of cognitive disorders in temporal lobe epilepsy. Nat Rev Neurol. 2011; 7(3):154-64. PMC: 3856217. DOI: 10.1038/nrneurol.2011.3. View

16.

Fredholm B, IJzerman A, Jacobson K, Linden J, Muller C . International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an update. Pharmacol Rev. 2011; 63(1):1-34. PMC: 3061413. DOI: 10.1124/pr.110.003285. View

17.

Fedele D, Koch P, Scheurer L, Simpson E, Mohler H, Brustle O . Engineering embryonic stem cell derived glia for adenosine delivery. Neurosci Lett. 2004; 370(2-3):160-5. DOI: 10.1016/j.neulet.2004.08.031. View

18.

Aronica E, Sandau U, Iyer A, Boison D . Glial adenosine kinase--a neuropathological marker of the epileptic brain. Neurochem Int. 2013; 63(7):688-95. PMC: 3676477. DOI: 10.1016/j.neuint.2013.01.028. View

19.

Frey L . Epidemiology of posttraumatic epilepsy: a critical review. Epilepsia. 2003; 44(s10):11-7. DOI: 10.1046/j.1528-1157.44.s10.4.x. View

20.

CANTONI G, Mudd S, Andreoli V . Affective disorders and S-adenosylmethionine: a new hypothesis. Trends Neurosci. 1989; 12(9):319-24. DOI: 10.1016/0166-2236(89)90038-6. View